Douglas Spitz

Professor

The University of Iowa
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (4)

Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive and chemo-resistant sarcomas with poor survival rates. Loss of CDKN2A or P53 following NF1 disruption is a key event in MPNST development. Here, we used CRISPR-Cas9 somatic tumorigenesis in mice to identify transcriptomic and metabolomic features distinguishing CDKN2A - versus P53 -deleted MPNSTs. Convergent, multiomic analyses revealed that CDKN2A -deleted MPNSTs are especially dependent on the pentose phosphate pathway (PPP) and NADPH metabolism for growth and viability. Disruption of glucose-6-phosphate dehydrogenase (G6PD), the PPP rate-limiting enzyme, slowed CDKN2A -deleted MPNST growth and sensitized MPNSTs to standard-of-care chemotherapy. Knockdown of the redox-regulated transcription factor NRF2 slowed MPNST growth and decreased G6PD transcription. Analysis of patient MPNSTs identified a NRF2 gene signature correlating with tumor transformation. Furthermore, G6PD and NRF2 expression in PanCancer TCGA samples correlates with patient survival. This work identifies NRF2-PPP dependency as a targetable vulnerability in these difficult-to-treat MPNSTs, particularly in the NF1/CDKN2A -deleted majority.

Year:

2025

Introduction Small cell lung cancer (SCLC) has a 7% 5-year overall survival. C-X-C chemokine receptor 4 (CXCR4), an attractive target for theranostic agents, is highly expressed in SCLCs, and can be targeted with pentixather using the theranostic pair 212 Pb/ 203 Pb. The hypothesis that [ 212 Pb/ 203 Pb]-pentixather can be used safely and effectively for imaging and therapy in SCLC in xenograft models was tested. Results SPECT/CT imaging and biodistribution studies of tumor bearing mice injected with [ 203 Pb]-pentixather demonstrated CXCR4-dependent uptake in tumors and accumulation of radioligand in kidneys and livers. Dosimetry calculations estimated [ 212 Pb]-pentixather uptake in tumor and normal tissue. [ 212 Pb]-pentixather treatment (37-111 kBq/g) of SCLC xenografts (DMS273 and H69AR) significantly prolonged survival and delayed tumor growth. When NSG mice grafted with human hCD34+ bone marrow were treated with [ 212 Pb]-pentixather (37-111 kBq/g), significant cytopenias were observed in peripheral blood complete blood counts (CBCs) at 13-18 days post treatment which resolved by day 28-31. Flow cytometry of bone marrow hematopeotic stem cells in these animals at day 28-31 demonstrated a significantly reduced frequency of the human hematopoietic marker CD45 (hCD45+) and reconstitution of the bone marrow with murine CD45+ (mCD45+) lineages. Conclusions [ 203 Pb]-pentixather can be used to image CXCR4 expressing SCLC xenografts and treatment with alpha emitter [ 212 Pb]-pentixather significantly prolongs SCLC xenograft median overall survival. Significantly greater mCD45+ bone marrow repopulation was detected in NSG mice engrafted with human bone marrow 28-31 days following [ 212 Pb]-pentixather treatment, relative to hCD45+ bone marrow.

Year:

2024

Purpose: Pharmacologic ascorbate (P-AscH − ) is hypothesized to be an iron (Fe)-dependent tumor-specific adjuvant to chemoradiation in treating glioblastoma (GBM). This study determined the efficacy of combining P-AscH − with radiation and temozolomide in a phase II clinical trial while simultaneously investigating a mechanism-based, noninvasive biomarker in T 2 * mapping to predict GBM response to P-AscH − in humans. Patients and Methods: The single-arm phase II clinical trial (NCT02344355) enrolled 55 subjects, with analysis performed 12 months following the completion of treatment. Overall survival (OS) and progression-free survival (PFS) were estimated with the Kaplan–Meier method and compared across patient subgroups with log-rank tests. Forty-nine of 55 subjects were evaluated using T 2 *-based MRI to assess its utility as an Fe-dependent biomarker. Results: Median OS was estimated to be 19.6 months [90% confidence interval (CI), 15.7–26.5 months], a statistically significant increase compared with historic control patients (14.6 months). Subjects with initial T 2 * relaxation 2 *-high subjects (11.2 months vs. 5.7 months, P in vitro and in vivo model systems. Conclusions: P-AscH − combined with temozolomide and radiotherapy has the potential to significantly enhance GBM survival. T 2 *-based MRI assessment of tumor iron content is a prognostic biomarker for GBM clinical outcomes. See related commentary by Nabavizadeh and Bagley, p. 255

Year:

2024

Purpose: Pharmacologic ascorbate (P-AscH − ) is hypothesized to be an iron (Fe)-dependent tumor-specific adjuvant to chemoradiation in treating glioblastoma (GBM). This study determined the efficacy of combining P-AscH − with radiation and temozolomide in a phase II clinical trial while simultaneously investigating a mechanism-based, noninvasive biomarker in T 2 * mapping to predict GBM response to P-AscH − in humans. Patients and Methods: The single-arm phase II clinical trial (NCT02344355) enrolled 55 subjects, with analysis performed 12 months following the completion of treatment. Overall survival (OS) and progression-free survival (PFS) were estimated with the Kaplan–Meier method and compared across patient subgroups with log-rank tests. Forty-nine of 55 subjects were evaluated using T 2 *-based MRI to assess its utility as an Fe-dependent biomarker. Results: Median OS was estimated to be 19.6 months [90% confidence interval (CI), 15.7–26.5 months], a statistically significant increase compared with historic control patients (14.6 months). Subjects with initial T 2 * relaxation 2 *-high subjects (11.2 months vs. 5.7 months, P in vitro and in vivo model systems. Conclusions: P-AscH − combined with temozolomide and radiotherapy has the potential to significantly enhance GBM survival. T 2 *-based MRI assessment of tumor iron content is a prognostic biomarker for GBM clinical outcomes. See related commentary by Nabavizadeh and Bagley, p. 255

Year:

2024

Collaborators (18)

John Buatti

Professor

The University of Iowa

UNITED STATES
View details

Kranti Mapuskar

Associate Research Scientist

The University of Iowa

UNITED STATES
View details

Stephen Graves

Associate Professor

The University of Iowa

UNITED STATES
View details

Adam Rauckhorst

Assistant Professor of Cellular and Molecular Medicine

Florida International University

UNITED STATES
View details

Nicholas Borcherding

Assistant Professor

University of Washington Medical Center

UNITED STATES
View details

Joseph J. Cullen

-

UNITED STATES
View details

Jeremy D. W. Greenlee

-

UNITED STATES
View details

Rebecca Dodd

Assistant Professor

The University of Iowa

UNITED STATES
View details

Brian Smith

Professor

Iowa State University

UNITED STATES
View details

Bryan Allen

Professor/Chair and DEO

University of Iowa Healthcare

UNITED STATES
View details

Varun Monga

Clinical Associate Professor

University of California San Francisco Medical Center

UNITED STATES
View details

Ryan Flynn

Medical Physics Division Director

The University of Iowa

UNITED STATES
View details

Vincent Magnotta

Professor

Iowa State University

UNITED STATES
View details

Garry Buettner

Professor

Iowa State University

UNITED STATES
View details

Muhammad Furqan

Professor

University of Oklahoma Health Sciences Center

UNITED STATES
View details

Jon Houtman

Professor

Iowa State University

UNITED STATES
View details

Joel J. St‐Aubin

-

UNITED STATES
View details

Karra A Jones

Associate Professor

Duke University

UNITED STATES
View details